Order Article Reprints

Costa Svedman F, Jalsenius M, Höiom V, Grozman V, Bergqvist M, Söderdahl F, Eriksson H, Rotstein S, Ny L, Ascierto PA, et al. Plasma Thymidine Kinase Activity as a Novel Biomarker in Metastatic Melanoma Patients Treated with Immune Checkpoint Inhibitors. Cancers. 2022; 14(3):702. https://doi.org/10.3390/cancers14030702

Costa Svedman, Fernanda, Marie Jalsenius, Veronica Höiom, Vitali Grozman, Mattias Bergqvist, Fabian Söderdahl, Hanna Eriksson, Samuel Rotstein, Lars Ny, Paolo A. Ascierto, and et al. 2022. "Plasma Thymidine Kinase Activity as a Novel Biomarker in Metastatic Melanoma Patients Treated with Immune Checkpoint Inhibitors" Cancers 14, no. 3: 702. https://doi.org/10.3390/cancers14030702

Costa Svedman, F., Jalsenius, M., Höiom, V., Grozman, V., Bergqvist, M., Söderdahl, F., Eriksson, H., Rotstein, S., Ny, L., Ascierto, P. A., Brage, S. E., & Helgadottir, H. (2022). Plasma Thymidine Kinase Activity as a Novel Biomarker in Metastatic Melanoma Patients Treated with Immune Checkpoint Inhibitors. Cancers, 14(3), 702. https://doi.org/10.3390/cancers14030702